Circulating XXXX Cells in Biochemical Recurrence of @entity263 .

@entity5 @entity1 @entity263
OBJECTIVE: Circulating @entity5 cells (CTCs) have known prognostic implications in metastatic castration-resistant @entity263 , but little is known regarding its utility in biochemical recurrence (BR) of @entity263 . The primary objectives were to determine whether CTCs are measurable in @entity1 with BR and whether it can reliably predict prostate-specific antigen (PSA) increase and PSA doubling times (PSADTs). METHODS: BR was identified in @entity1 after prostatectomy or radiation or both, with a PSA increase of  >=  0.2 for prior prostatectomy or > 2 mg/dL increase for post-nadir in prior radiotherapy. CTCs were enumerated at baseline at the time of study entry using the CellSearch (Janssen Diagnostics, Raritan, NJ) test. RESULTS: The median age for all 36 @entity1 accrued was 69.5 years (range, 51-91) with a median PSA of 1.65 ng/mL (range, 0.2-65.8). Gleason scores ranged from 5 to 9 (median, 7). The majority had prostatectomy (n  = 25), external beam radiotherapy (n  = 9), CyberKnife (Accuray, Sunnyvale, CA) (n  = 1), and combined radiohormonal therapy (n  = 1). PSADT ranged from 0.35 to 55 months, with a median of 7.43 months. The incidence of positive CTCs was 8.3% (3 @entity1 ), of whom 2 had biopsy-proven bony lesions on presenting with equivocal scans and PSADTs of 2.27 and 3.08 months, respectively. The third CTC-positive @entity1 had a PSADT of 4.99 months. CONCLUSIONS: Obtaining CTCs in unselected @entity1 presenting with BR has a relatively low yield. However, obtaining a positive CTC raises the suspicion of the presence of metastatic disease and may have utility for longitudinal follow-ups of @entity1 with BR.
